TECH vs. NBIX, QGEN, RGEN, PCVX, RVMD, EXEL, HALO, ARGX, KRYS, and IBRX
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), argenx (ARGX), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "medical" sector.
Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
Neurocrine Biosciences received 597 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
Neurocrine Biosciences has a net margin of 18.65% compared to Neurocrine Biosciences' net margin of 17.59%. Bio-Techne's return on equity of 17.45% beat Neurocrine Biosciences' return on equity.
Neurocrine Biosciences currently has a consensus target price of $150.85, indicating a potential upside of 12.05%. Bio-Techne has a consensus target price of $81.00, indicating a potential upside of 3.05%. Given Bio-Techne's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Bio-Techne.
In the previous week, Neurocrine Biosciences had 9 more articles in the media than Bio-Techne. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 11 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.76 beat Neurocrine Biosciences' score of 0.69 indicating that Neurocrine Biosciences is being referred to more favorably in the media.
Neurocrine Biosciences has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 4.1% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Bio-Techne has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Summary
Neurocrine Biosciences beats Bio-Techne on 14 of the 19 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
